JP7234151B2 - 脂肪酸誘導体およびこれらの使用 - Google Patents

脂肪酸誘導体およびこれらの使用 Download PDF

Info

Publication number
JP7234151B2
JP7234151B2 JP2019572570A JP2019572570A JP7234151B2 JP 7234151 B2 JP7234151 B2 JP 7234151B2 JP 2019572570 A JP2019572570 A JP 2019572570A JP 2019572570 A JP2019572570 A JP 2019572570A JP 7234151 B2 JP7234151 B2 JP 7234151B2
Authority
JP
Japan
Prior art keywords
compound
hydrogen
subject
epoxy
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019572570A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526505A5 (enExample
JP2020526505A (ja
Inventor
クリストファー ラムスデン，
グレゴリー キーズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of JP2020526505A publication Critical patent/JP2020526505A/ja
Publication of JP2020526505A5 publication Critical patent/JP2020526505A5/ja
Application granted granted Critical
Publication of JP7234151B2 publication Critical patent/JP7234151B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
    • C07C33/025—Acyclic alcohols with carbon-to-carbon double bonds with only one double bond
    • C07C33/03—Acyclic alcohols with carbon-to-carbon double bonds with only one double bond in beta-position, e.g. allyl alcohol, methallyl alcohol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • C07D303/42—Acyclic compounds having a chain of seven or more carbon atoms, e.g. epoxidised fats
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019572570A 2017-07-07 2018-07-06 脂肪酸誘導体およびこれらの使用 Active JP7234151B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762529846P 2017-07-07 2017-07-07
US62/529,846 2017-07-07
PCT/US2018/041086 WO2019010414A1 (en) 2017-07-07 2018-07-06 FATTY ACID DERIVATIVES AND USE THEREOF

Publications (3)

Publication Number Publication Date
JP2020526505A JP2020526505A (ja) 2020-08-31
JP2020526505A5 JP2020526505A5 (enExample) 2021-07-26
JP7234151B2 true JP7234151B2 (ja) 2023-03-07

Family

ID=63036390

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019572570A Active JP7234151B2 (ja) 2017-07-07 2018-07-06 脂肪酸誘導体およびこれらの使用

Country Status (9)

Country Link
US (2) US11555021B2 (enExample)
EP (1) EP3649115B1 (enExample)
JP (1) JP7234151B2 (enExample)
KR (1) KR102725883B1 (enExample)
CN (1) CN110869354A (enExample)
AU (1) AU2018297192B2 (enExample)
CA (1) CA3064132C (enExample)
MX (1) MX391168B (enExample)
WO (1) WO2019010414A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018070164B1 (pt) 2016-04-01 2022-09-27 Sony Corporation Of America Corantes diméricos ou poliméricos ultrabrilhantes
CN109153860B (zh) 2016-04-06 2021-04-23 索尼公司 具有间隔连接体基团的超高亮二聚体或聚合物染料
WO2018022925A1 (en) 2016-07-29 2018-02-01 Sony Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
US12290571B2 (en) 2017-10-05 2025-05-06 Sony Group Corporation Programmable dendritic drugs
KR20260011205A (ko) 2017-10-05 2026-01-22 소니그룹주식회사 프로그램가능한 중합체성 약물
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
US12076407B2 (en) 2018-01-12 2024-09-03 Sony Group Corporation Polymers with rigid spacing groups comprising biologically active compounds
EP3737417B1 (en) 2018-01-12 2025-08-27 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
KR102864292B1 (ko) 2018-03-21 2025-09-26 소니그룹주식회사 링커 군을 갖는 중합체성 텐덤 염료
JP7580689B2 (ja) 2018-06-27 2024-11-12 ソニーグループ株式会社 デオキシリボースを含むリンカー基を有するポリマー色素
US12578342B2 (en) 2018-07-13 2026-03-17 Sony Group Corporation Polymeric dyes having a backbone comprising organophosphate units
EP3861074A2 (en) 2019-09-26 2021-08-11 Sony Group Corporation Polymeric tandem dyes with linker groups
EP4038081A1 (en) 2019-09-30 2022-08-10 Sony Group Corporation Nucleotide probes
EP4256078A1 (en) 2020-12-07 2023-10-11 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes
CN113121475B (zh) * 2021-03-30 2022-12-02 香港科技大学深圳研究院 不饱和脂肪酸类化合物及其制备方法和应用
CN113620923B (zh) * 2021-07-16 2023-03-14 扬州工业职业技术学院 一种低温电解液添加剂的制备方法及应用
CN115073295B (zh) * 2022-07-21 2023-12-26 山东大学 马齿苋中不饱和脂肪酸及其提取分离方法和应用
WO2024237316A1 (ja) * 2023-05-16 2024-11-21 国立大学法人東京大学 エポキシ化不飽和脂肪酸の皮膚線維化改善作用
EP4613730A1 (en) * 2024-03-05 2025-09-10 Centre National de la Recherche Scientifique Lipidic alkynylcarbinols with anti-bacterial and anti-tuberculosis activity

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198814A1 (en) 2000-10-11 2004-10-07 Dasseux Jean-Louis Henri Ketone compounds and compositions for cholesterol management and related uses
JP2006513251A (ja) 2003-01-23 2006-04-20 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物
WO2008104976A1 (en) 2007-02-26 2008-09-04 Syndromex Ltd. Amphipathic carboxylates for the treatment of immune-related disorders
JP2012502035A (ja) 2008-09-04 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のインドリジン阻害剤
JP2015518484A (ja) 2012-04-19 2015-07-02 ナイケン ホールディング ベーフェー ゲラニルゲラニルアセトン類似化合物及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055613A (en) * 1988-02-18 1991-10-08 G. D. Searle & Co. Metabolites of pentanedioic acid derivatives
ATE168372T1 (de) * 1993-03-29 1998-08-15 Hsc Res Dev Lp Hepoxilin analoga verwendbar als entzündungshemmende mittel
IL121165A0 (en) * 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US20020037876A1 (en) * 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
BR0012447A (pt) * 1999-07-15 2002-04-02 Lilly Co Eli Análogos de pseudomicina de cadeia lateral de n-acila
DE102004037118A1 (de) 2004-07-30 2006-03-23 Degussa Ag Titandioxid enthaltende Dispersion
WO2006106438A2 (en) 2005-01-11 2006-10-12 Evolva Sa Modulators of ppar activity
JP5337479B2 (ja) 2005-05-04 2013-11-06 プロノヴァ・バイオファーマ・ノルゲ・アーエス 新規化合物
JP6160375B2 (ja) 2013-09-06 2017-07-12 ブラザー工業株式会社 画像記録装置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198814A1 (en) 2000-10-11 2004-10-07 Dasseux Jean-Louis Henri Ketone compounds and compositions for cholesterol management and related uses
JP2006513251A (ja) 2003-01-23 2006-04-20 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物
WO2008104976A1 (en) 2007-02-26 2008-09-04 Syndromex Ltd. Amphipathic carboxylates for the treatment of immune-related disorders
JP2012502035A (ja) 2008-09-04 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のインドリジン阻害剤
JP2015518484A (ja) 2012-04-19 2015-07-02 ナイケン ホールディング ベーフェー ゲラニルゲラニルアセトン類似化合物及びその使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Burger, Alain et al.，Mechanism-based inhibitors of prostaglandin ω-hydroxylase: (R)- and (S)-12-hydroxy-16-heptadecynoic acid and 2,2-dimethyl-12-hydroxy-16-heptadecynoic acid，Journal of Medicinal Chemistry，1993年，Vol.36, No.10，pp.1418-24
Hara, Shoji et al.，The Regioselective 1,4-Addition Reaction of Alkenylboronic Acids to α,β,α',β'-Unsaturated Ketones，Bulletin of the Chemical Society of Japan ，1998年，Vol.71, No.10，pp.2403-2408
Hoye, Thomas R. et al.，A [W(CO)5・THF]-mediated Pauson-Khand reaction: cyclizations of 1,6-enynes via a batch-catalytic protocol，Journal of the American Chemical Society，1993年，Vol.115, No.3，pp.1154-6
Kodama, Mitsuaki et al.，Synthesis of macrocyclic terpenoids by intramolecular cyclization. XI. Total synthesis of zerumbone，Chemical & Pharmaceutical Bulletin ，1987年，Vol.35, No.10，pp.4039-42
Mizota, Isao et al.，Exploration into a new dicarboxylic acid derived from ricinoleic acid for high-performance aluminum electrolytic capacitors，Bulletin of the Chemical Society of Japan ，2016年，Vol.89，No.11，pp.1368-1374

Also Published As

Publication number Publication date
EP3649115B1 (en) 2024-09-04
KR102725883B1 (ko) 2024-11-01
EP3649115A1 (en) 2020-05-13
AU2018297192B2 (en) 2022-02-17
US20220274940A1 (en) 2022-09-01
AU2018297192A1 (en) 2019-12-19
US20210139440A1 (en) 2021-05-13
CN110869354A (zh) 2020-03-06
MX391168B (es) 2025-03-21
WO2019010414A1 (en) 2019-01-10
CA3064132C (en) 2024-06-04
US12479812B2 (en) 2025-11-25
JP2020526505A (ja) 2020-08-31
KR20200027545A (ko) 2020-03-12
CA3064132A1 (en) 2019-01-10
EP3649115C0 (en) 2024-09-04
US11555021B2 (en) 2023-01-17

Similar Documents

Publication Publication Date Title
US12479812B2 (en) Fatty acid derivatives and their use
Aursnes et al. Total synthesis of the lipid mediator PD1n-3 DPA: configurational assignments and anti-inflammatory and pro-resolving actions
Sun et al. Development and mechanism investigation of a new piperlongumine derivative as a potent anti-inflammatory agent
Batsika et al. Saturated oxo fatty acids (SOFAs): A previously unrecognized class of endogenous bioactive lipids exhibiting a cell growth inhibitory activity
Levy Resolvins and protectins: natural pharmacophores for resolution biology
CA3005760C (en) Compounds and methods for inhibiting production of trimethylamine
ES2773784T3 (es) Enantiómeros de 2-hidroxiderivados de ácidos grasos
JP6820312B2 (ja) アトルバスタチンにより増加し、炎症を消失させる新規な１３−シリーズのレゾルビンの解明
JP2021525803A (ja) カンナビノイド及びそれらの使用
Wei et al. Structure-based optimization and biological evaluation of pancreatic lipase inhibitors as novel potential antiobesity agents
JPS6112907B2 (enExample)
WO2019152847A1 (en) Disease detection and treatment based on trimethyl-lysine levels
EP2163557A1 (en) Function-selective vitamin d receptor agonist
Stepniewski et al. Synthesis, molecular modelling studies and biological evaluation of new oxoeicosanoid receptor 1 agonists
WO2020245291A1 (en) Pyrrole derivatives as acc inhibitors
Ervik et al. Synthesis of the methyl ester of 17 (R/S)-Me-RvD5n-3 DPA and relief of postoperative pain in male mice
JP2019055913A (ja) ビタミンｄ活性を有するリトコール酸誘導体
CN107880094B (zh) 熊果酸类中性胆固醇酯水解酶抑制剂及其应用
NIU et al. Enhancing bioactivities and chemical properties of A marine briarane-type diterpenoid with late-stage diversification
US20260022089A1 (en) Quinone-derived compounds and use thereof against leishmania spp
EP3204000B1 (en) Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
WO2024073673A1 (en) Modulators of cd1 protein binding to t cell receptors
RU2712229C2 (ru) Эфиры тригидроксигептаеновой кислоты в качестве агонистов fpr2 рецептора
WO2005005433A1 (ja) 高カルシウム血症および骨疾患治療剤
Chen et al. Targeting Autotaxin for Therapeutic Intervention

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210511

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230222

R150 Certificate of patent or registration of utility model

Ref document number: 7234151

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250